급성 호흡곤란 증후군(ARDS) 시장 보고서(2025년)

Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

급성 호흡곤란 증후군(ARDS) 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간의 성장은 글로벌 의료 대비, 백신 개발 및 전염병 관리, 원격 의료 및 원격 모니터링, 환자 중심 치료 모델에 기인할 수 있습니다. 예측 기간의 주요 동향은 인공 폐 장치, 개별화된 환기 전략, 폐 보호 환기, 급성 호흡 곤란 아형에 대한 약수처리 등이 있습니다.

폐렴의 유병률 증가는 급성 호흡곤란 증후군(ARDS) 시장 성장을 견인할 것으로 예상됩니다. 이것은 혈관 투과성을 증가시키는 염증 반응을 일으키고, 액체가 폐포로 누출되어 산소와 이산화탄소의 교환이 손상되어 호흡 곤란을 일으킵니다. 2023년 11월, 영국을 기반으로 한 건강 관리 연구의 선두 주자인 열대 의학 및 세계 건강 센터는 케냐에서 폐렴 환자의 상당한 증가를 보고했으며, 그 수는 2020-2021년 477,186명에서 2022-2023년에는 793,864명으로 증가했습니다. 그 결과 폐렴의 유병률 증가가 급성 호흡곤란 증후군(ARDS) 시장 확대를 촉진하고 있습니다.

호흡기 질환의 이환율 증가는 급성 호흡곤란 증후군(ARDS) 시장 성장을 가속할 것으로 예상됩니다. COVID-19를 포함한 호흡기 질환 증가는 급성 호흡곤란 증후군(ARDS) 시장 성장에 기여하는 중요한 요인입니다. 2023년 11월 미국 정부기관인 노동통계국에 따르면 2022년 민간기업 고용자 발병률은 풀타임 환산(FTE) 노동자 1만명당 45.2건으로 2021년 37.7건에서 증가했습니다. 이 증가의 주요 원인은 호흡기 질환 증가이며, 2021년 FTE 노동자 1만명당 27.8건에서 2022년에는 35.8건으로 급증했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 급성 호흡곤란 증후군(ARDS) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업의 분석
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 성장률 분석
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 급성 호흡곤란 증후군(ARDS) 전체 시장(TAM)

제6장 시장 세분화

• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 유형별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 진단
• 치료
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 원인별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 2019 신종 코로나바이러스 감염증(COVID-19)
• 패혈증
• 유해 물질 흡입
• 중증 폐렴
• 기타 원인
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 중증도별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 경증
• 보통
• 심각
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 최종 사용자별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 외래 서비스 센터
• 기타 최종 사용자
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 진단 유형별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 영상 검사
• 혈액 검사
• 폐 기능 검사
• 기타 진단 방법
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 치료 유형별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 기계식 인공호흡기
• 약물 치료
• 체외막 산소화(ECMO)
• 지지적 치료
• 기타 치료 옵션

제7장 지역별/국가별 분석

• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 지역별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 급성 호흡곤란 증후군(ARDS) 시장 : 국가별, 분석 및 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 급성 호흡곤란 증후군(ARDS) 시장 : 경쟁 구도
• 급성 호흡곤란 증후군(ARDS) 시장 : 기업 프로파일
  • Johnson & Johnson Services Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc 개요, 제품 및 서비스, 전략 및 재무 분석
  • Medtronic plc 개요, 제품 및 서비스, 전략 및 재무 분석
  • Boehringer Ingelheim International GmbH 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Gilead Sciences Inc.
• Amgen Inc.
• Fresenius SE & Co. KGaA
• Koninklijke Philips NV
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• CSL Behring
• Terumo Corporation
• ResMed Inc.
• Smiths Medical Inc.
• Drager Safety AG & Co. KGaA.
• Getinge AB
• Mallinckrodt plc
• Masimo Corporation
• United Therapeutics Corporation

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 급성 호흡곤란 증후군(ARDS) 시장(2029년) : 새로운 기회를 제공하는 국가
• 급성 호흡곤란 증후군(ARDS) 시장(2029년) : 새로운 기회를 제공하는 부문
• 급성 호흡곤란 증후군(ARDS) 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Acute Respiratory Distress Syndrome (ARDS) is a potentially life-threatening condition characterized by rigid, non-compliant lungs and inadequate oxygenation. This condition presents as an acute, widespread inflammatory lung injury that can affect critically ill patients. The primary approach to treating ARDS involves employing mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygen levels and minimize further lung damage.

The key facets of dealing with Acute Respiratory Distress Syndrome (ARDS) pertain to its diagnosis and treatment. Diagnosis encompasses the process of distinguishing this condition from other potential disorders and delineating its characteristics. The diagnosis of ARDS typically relies on a physical examination, chest X-ray, and oxygenation levels. ARDS can be triggered by various factors such as COVID-19 (COVID-19 Disease 2019), sepsis, exposure to harmful substances, severe pneumonia, among others, with its severity ranging from mild to moderate and severe. The primary recipients of ARDS-related services include hospitals, clinics, ambulatory service centers, and other healthcare facilities.

The acute respiratory distress syndrome (ARDS) market research report is one of a series of new reports from The Business Research Company that provides acute respiratory distress syndrome (ARDS) market statistics, including acute respiratory distress syndrome (ARDS) industry global market size, regional shares, competitors with an acute respiratory distress syndrome (ARDS) market share, detailed acute respiratory distress syndrome (ARDS) market segments, market trends and opportunities and any further data you may need to thrive in the acute respiratory distress syndrome (ARDS) industry. This acute respiratory distress syndrome (ARDS) market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute respiratory distress syndrome (ARDS) market size has grown rapidly in recent years. It will grow from $1.29 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to advancements in critical care medicine, aging population, pulmonary rehabilitation, multidisciplinary care teams.

The acute respiratory distress syndrome (ARDS) market size is expected to see rapid growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to global healthcare preparedness, vaccine development and infectious disease management, telemedicine and remote monitoring, patient-centered care models. Major trends in the forecast period include artificial lung devices, personalized ventilation strategies, lung protective ventilation, drug therapies for ards subtypes.

The increasing prevalence of pneumonia is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Pneumonia is an infection that affects one or both lungs, leading to the accumulation of fluid or pus in the alveoli, or air sacs of the lungs. This causes an inflammatory reaction that increases blood vessel permeability, allowing fluid to leak into the alveoli and impairing the exchange of oxygen and carbon dioxide, resulting in respiratory distress. For example, in November 2023, the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, reported a significant rise in pneumonia cases in Kenya, which increased from 477,186 in 2020-2021 to 793,864 in 2022-2023. As a result, the growing prevalence of pneumonia is driving the expansion of the ARDS market.

The rising incidence of respiratory illnesses is expected to drive the growth of the acute respiratory distress syndrome (ARDS) market. Respiratory illnesses encompass a range of medical conditions that affect the airways and lungs, often causing difficulty in breathing. The increasing number of respiratory illnesses, including COVID-19, is a significant factor contributing to the growth of the ARDS market. As more individuals develop respiratory conditions, the demand for ARDS treatments and therapies is likely to rise, boosting market expansion. For instance, in November 2023, the Bureau of Labor Statistics, a US-based government agency, reported that in 2022, the illness rate among private industry employers increased to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This increase was largely attributed to a rise in respiratory illnesses, which jumped from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the growing number of respiratory illnesses is driving the expansion of the ARDS market.

Prominent companies operating within the acute respiratory distress syndrome (ARDS) market are dedicating their efforts to the creation of groundbreaking drugs and supplements, including Aviptadil and HSP90 inhibitors, aimed at reinforcing their market position. Aviptadil, a synthetic vasoactive intestinal peptide (VIP), is designed to specifically target receptors on lung alveolar type II cells. For instance, in November 2022, Zuventus Healthcare Ltd., an Indian pharmaceutical manufacturing company, introduced Aviptadil as a treatment for acute respiratory distress syndrome. Aviptadil, functioning as a vasoactive intestinal peptide supplement, enhances breathing and reduces mortality in ARDS patients. This is achieved through Aviptadil's capacity to safeguard and regenerate Type-2 Pneumocytes, restore Type-1 Pneumocytes, increase surfactant synthesis, and suppress interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

In January 2022, AcelRx Pharmaceuticals Inc., a specialized pharmaceutical company based in the United States, acquired Lowell Therapeutics Inc. for $32.5 million. This strategic acquisition empowers AcelRx Pharmaceuticals to expand its product portfolio and solidify its standing in the pharmaceutical industry. Lowell Therapeutics Inc., also based in the U.S., is a pharmaceutical company dedicated to developing products for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC).

Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Drager Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute respiratory distress syndrome (ARDS) market includes revenues earned by entities by providing resolution and recovery services, medication, supplemental oxygen and mechanical ventilation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute respiratory distress syndrome (ARDS) market consists of sales of neuromuscular blockers, corticosteroids, monitoring devices, diagnostic devices and therapeutic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Respiratory Distress Syndrome (ARDS) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute respiratory distress syndrome (ards) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute respiratory distress syndrome (ards) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute respiratory distress syndrome (ards) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Diagnosis; Treatment
• 2) By Cause: COVID-19 Disease 2019 (COVID-19); Sepsis; Inhalation Of Harmful Substances; Severe Pneumonia; Other Causes
• 3) By Severity: Mild; Moderate; Severe
• 4) By End User: Hospitals; Clinics; Ambulatory Service Centers; Other End Users
• Subsegments:
• 1) By Diagnosis: Imaging Tests; Blood Tests; Lung Function Tests; Other Diagnostic Methods
• 2) By Treatment: Mechanical Ventilation; Medications; Extracorporeal Membrane Oxygenation (ECMO); Supportive Care; Other Treatment Options
• Companies Mentioned: Johnson & Johnson Services Inc.; Novartis AG; GlaxoSmithKline plc; Medtronic plc; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Respiratory Distress Syndrome (ARDS) Market Characteristics

3. Acute Respiratory Distress Syndrome (ARDS) Market Trends And Strategies

4. Acute Respiratory Distress Syndrome (ARDS) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Acute Respiratory Distress Syndrome (ARDS) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Respiratory Distress Syndrome (ARDS) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Respiratory Distress Syndrome (ARDS) Market Growth Rate Analysis
• 5.4. Global Acute Respiratory Distress Syndrome (ARDS) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Respiratory Distress Syndrome (ARDS) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Respiratory Distress Syndrome (ARDS) Total Addressable Market (TAM)

6. Acute Respiratory Distress Syndrome (ARDS) Market Segmentation

• 6.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis
• Treatment
• 6.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COVID-19 Disease 2019 (COVID-19)
• Sepsis
• Inhalation Of Harmful Substances
• Severe Pneumonia
• Other Causes
• 6.3. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild
• Moderate
• Severe
• 6.4. Global Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Ambulatory Service Centers
• Other End Users
• 6.5. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Diagnosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Blood Tests
• Lung Function Tests
• Other Diagnostic Methods
• 6.6. Global Acute Respiratory Distress Syndrome (ARDS) Market, Sub-Segmentation Of Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mechanical Ventilation
• Medications
• Extracorporeal Membrane Oxygenation (ECMO)
• Supportive Care
• Other Treatment Options

7. Acute Respiratory Distress Syndrome (ARDS) Market Regional And Country Analysis

• 7.1. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Respiratory Distress Syndrome (ARDS) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market

• 8.1. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Respiratory Distress Syndrome (ARDS) Market

• 9.1. China Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 9.2. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Respiratory Distress Syndrome (ARDS) Market

• 10.1. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Respiratory Distress Syndrome (ARDS) Market

• 11.1. Japan Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 11.2. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Respiratory Distress Syndrome (ARDS) Market

• 12.1. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market

• 13.1. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Respiratory Distress Syndrome (ARDS) Market

• 14.1. South Korea Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 14.2. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market

• 15.1. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 15.2. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Respiratory Distress Syndrome (ARDS) Market

• 16.1. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Respiratory Distress Syndrome (ARDS) Market

• 17.1. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Respiratory Distress Syndrome (ARDS) Market

• 18.1. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Respiratory Distress Syndrome (ARDS) Market

• 19.1. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Respiratory Distress Syndrome (ARDS) Market

• 20.1. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market

• 21.1. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 21.2. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Respiratory Distress Syndrome (ARDS) Market

• 22.1. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Respiratory Distress Syndrome (ARDS) Market

• 23.1. North America Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 23.2. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Respiratory Distress Syndrome (ARDS) Market

• 24.1. USA Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 24.2. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Respiratory Distress Syndrome (ARDS) Market

• 25.1. Canada Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 25.2. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Respiratory Distress Syndrome (ARDS) Market

• 26.1. South America Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 26.2. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Respiratory Distress Syndrome (ARDS) Market

• 27.1. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Respiratory Distress Syndrome (ARDS) Market

• 28.1. Middle East Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 28.2. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Respiratory Distress Syndrome (ARDS) Market

• 29.1. Africa Acute Respiratory Distress Syndrome (ARDS) Market Overview
• 29.2. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Respiratory Distress Syndrome (ARDS) Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape And Company Profiles

• 30.1. Acute Respiratory Distress Syndrome (ARDS) Market Competitive Landscape
• 30.2. Acute Respiratory Distress Syndrome (ARDS) Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis

31. Acute Respiratory Distress Syndrome (ARDS) Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Amgen Inc.
• 31.3. Fresenius SE & Co. KGaA
• 31.4. Koninklijke Philips N.V.
• 31.5. Baxter International Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. CSL Behring
• 31.8. Terumo Corporation
• 31.9. ResMed Inc.
• 31.10. Smiths Medical Inc.
• 31.11. Drager Safety AG & Co. KGaA.
• 31.12. Getinge AB
• 31.13. Mallinckrodt plc
• 31.14. Masimo Corporation
• 31.15. United Therapeutics Corporation

32. Global Acute Respiratory Distress Syndrome (ARDS) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Respiratory Distress Syndrome (ARDS) Market

34. Recent Developments In The Acute Respiratory Distress Syndrome (ARDS) Market

35. Acute Respiratory Distress Syndrome (ARDS) Market High Potential Countries, Segments and Strategies

• 35.1 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Respiratory Distress Syndrome (ARDS) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료